Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1083525

registered interest
date	07/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent steps he has taken to widen access to blood glucose monitoring technology for diabetes patients.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	229721
answer	answer is ministerial correction date of answer 15/03/2019 answer text <p>Glucose monitoring technology, such as continuous glucose monitoring or blood glucose test strips, will continue to be available to those meeting the relevant clinical criteria.</p><p> </p><p>In November 2018, NHS England announced that it will ensure that flash glucose monitoring is available on prescription for all patients who qualify for it in line with current recommendations. From April 2019, all qualifying patients will be able to receive it from their local general practitioner or diabetes team.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/03/2019 12:24:05 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

1129746

registered interest
date	04/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans he has to increase access to the Freestyle Libre monitoring device for diabetes patients.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	259980
answer	answer is ministerial correction date of answer 12/06/2019 answer text <p>Glucose monitoring technology, such as flash glucose monitors like Freestyle Libre will continue to be available to those meeting the relevant clinical criteria.</p><p>The NHS Long Term Plan announced that the National Health Service will ensure that, in line with clinical guidelines, eligible patients with type 1 diabetes benefit from life changing flash glucose monitors from April 2019, ending the variation patients in some parts of the country are facing.</p><p>NHS England has published detailed criteria and supporting guidance at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2019/03/flash-glucose-monitoring-national-arrangements-funding-v1.1.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2019/03/flash-glucose-monitoring-national-arrangements-funding-v1.1.pdf</a></p><p> </p><p>Clinical commissioning groups (CCGS) will be reimbursed for the cost of flash glucose monitoring sensors for those who meet these criteria, which could amount to up to 20% of their type 1 diabetes populations. CCGs can also locally choose to fund flash glucose monitoring for other patients with diabetes. The guidance advises that as part of their annual review process, patients with diabetes should be assessed for suitability for flash glucose monitoring. This process can also form part of a review for a different purpose, if that occurs earlier. This will promote a systematic approach to increasing take up.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 259981 question first answered 12/06/2019 16:02:36 answering member 4455 label Biography information for Seema Kennedy
tabling member	4079 label Biography information for Julian Sturdy

1129747

registered interest
date	04/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure equitable access to the Freestyle Libre monitoring device for diabetes patients on the NHS.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	259981
answer	answer is ministerial correction date of answer 12/06/2019 answer text <p>Glucose monitoring technology, such as flash glucose monitors like Freestyle Libre will continue to be available to those meeting the relevant clinical criteria.</p><p>The NHS Long Term Plan announced that the National Health Service will ensure that, in line with clinical guidelines, eligible patients with type 1 diabetes benefit from life changing flash glucose monitors from April 2019, ending the variation patients in some parts of the country are facing.</p><p>NHS England has published detailed criteria and supporting guidance at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2019/03/flash-glucose-monitoring-national-arrangements-funding-v1.1.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2019/03/flash-glucose-monitoring-national-arrangements-funding-v1.1.pdf</a></p><p> </p><p>Clinical commissioning groups (CCGS) will be reimbursed for the cost of flash glucose monitoring sensors for those who meet these criteria, which could amount to up to 20% of their type 1 diabetes populations. CCGs can also locally choose to fund flash glucose monitoring for other patients with diabetes. The guidance advises that as part of their annual review process, patients with diabetes should be assessed for suitability for flash glucose monitoring. This process can also form part of a review for a different purpose, if that occurs earlier. This will promote a systematic approach to increasing take up.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 259980 question first answered 12/06/2019 16:02:36 answering member 4455 label Biography information for Seema Kennedy
tabling member	4079 label Biography information for Julian Sturdy

1166923

registered interest
date	28/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to widen the NHS England criteria under which diabetes patients can receive the Freestyle Libre glucose monitoring device on prescription to include type 2 diabetics.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	6361
answer	answer is ministerial correction date of answer 05/11/2019 answer text <p>Clinical commissioning groups are responsible for commissioning diabetes services for their local populations. They are also expected to take National Institute for Health and Care Excellence (NICE) guidelines into consideration when making their decisions. NICE currently recommends not routinely offering self-monitoring of blood glucose levels for adults with type 2 diabetes unless the person:</p><p> </p><p>- is on insulin;</p><p>- or there is evidence of hypoglycaemic episodes;</p><p>- or the person is on medication that may increase their risk of hypoglycaemia while driving or operating machinery;</p><p>- or the person is pregnant or is planning to become pregnant.</p><p> </p><p>The evidence base for the benefits and cost-effectiveness of flash glucose monitoring for people with type 2 diabetes is still developing, and NICE will continue to monitor the evidence and relevant research.</p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 05/11/2019 10:24:50 answering member 4380 label Biography information for Jo Churchill
tabling member	4079 label Biography information for Julian Sturdy

1251392

registered interest
date	12/11/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will instruct NHS England to amend the guidelines they issue to clinical commissioning groups to extend the criteria for the prescription of the freestyle libre glucose monitoring device to people diagnosed with Type 2 diabetes.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	114850
answer	answer is ministerial correction date of answer 24/11/2020 answer text <p>The criteria for being prescribed the freestyle libre glucose monitoring device were extended on 11 November 2020 to include both people with Type 1 diabetes and people who have insulin treated Type 2 diabetes who are living with a learning disability and who are recorded on their general practitioner’s learning disability register.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 24/11/2020 16:04:10 answering member 4380 label Biography information for Jo Churchill
tabling member	4079 label Biography information for Julian Sturdy

1648936

registered interest
date	29/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of making (a) the Dexcom G6 Continuous Glucose Monitor and (b) other glucose sensors available to people with type-one diabetes.
tabling member constituency	Weaver Vale
tabling member printed	Mike Amesbury
uin	191862
answer	answer is ministerial correction date of answer 04/07/2023 answer text <p>Both intermittent and real-time Continuous Glucose Monitors (CGMs) are available to people with type one diabetes under the NHS. CGMs can be provided under NHS prescription and sensors collected from local pharmacies.</p><p>The Dexcom One is one model of CGM that is available under the NHS. Currently the Dexcom G6 model is being considered for provision as part of the Hybrid Closed Loop (HCL) system. The HCL system includes a higher specification CGM with an algorithm that ‘speaks’ to the insulin pump to adjust the amount of insulin the pump is administering as necessary.</p><p>The National Institute for Health and Care Excellence have been assessing the cost effectiveness of HCL and are due to publish their recommendations soon.</p><p>Different HCL systems are available and some are built by combining interoperable devices from different companies. Because of the large number of combinations of components available to the NHS, this appraisal considers HCL systems as a class of technologies rather than individual components or systems. The Dexcom G6 is included in this assessment.</p><p>Hybrid closed loops systems are only recommended if the companies and NHS England agree a cost-effective price for the systems on behalf of the relevant health bodies.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 04/07/2023 14:40:08 answering member 4527 label Biography information for Helen Whately
tabling member	4667 label Biography information for Mike Amesbury

1104798

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans the Government and NHS England have to ensure that CCGs use the funding allocated nationally to prescribe Flash Glucose Monitoring from 1 April 2019 using central NHS criteria.
tabling member constituency	Wakefield
tabling member printed	Mary Creagh
uin	236412
answer	answer is ministerial correction date of answer 29/03/2019 answer text <p>In November 2018, NHS England announced action to end the current variation in accessing flash glucose monitors. From April 2019 there will be a more consistent national approach to making these devices available. Clinical commissioning groups (CCGs) will be reimbursed to cover the costs of flash glucose monitoring sensors for those type 1 diabetes patients who are most likely to benefit from their use. NHS England has published detailed criteria and supporting guidance at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2019/03/flash-glucose-monitoring-national-arrangements-funding.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2019/03/flash-glucose-monitoring-national-arrangements-funding.pdf</a></p><p> </p><p>CCGs will be reimbursed for the cost of flash glucose monitoring sensors for those who meet these criteria, which could amount to up to 20% of their type 1 diabetes populations. CCGs can also locally choose to fund flash glucose monitoring for other patients with diabetes. The guidance advises that as part of their annual review process, patients with diabetes should be assessed for suitability for flash glucose monitoring. This process can also form part of a review for a different purpose, if that occurs earlier. This will promote a systematic approach to increasing take up.</p><p> </p><p>NHS England has engaged with NHS Clinical Commissioners, the membership organisation for CCGs, regarding the planned arrangements so that they can advise their members as appropriate. An FAQ for patients and commissioners is also being prepared and will be published, to aid the implementation. NHS England is also in conversations with the Academic Health Science Network to identify the capacity and scope for them to aid in rolling out flash glucose monitoring.</p><p> </p><p>Due to the limitations of the data collected by the NHS Business Services Authority, it is not possible to conclusively state which CCGs do or do not currently prescribe flash glucose monitors.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 236413 236414 question first answered 29/03/2019 14:47:45 answering member 4008 label Biography information for Dame Caroline Dinenage previous answer version 110760 answering member constituency Gosport answering member printed Caroline Dinenage answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1579 label Biography information for Mary Creagh

1104799

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps NHS England is taking to encourage CCGs which do not prescribe Flash Glucose Monitoring technology to do so as soon as possible when new guidance comes into effect from 1 April 2019.
tabling member constituency	Wakefield
tabling member printed	Mary Creagh
uin	236413
answer	answer is ministerial correction date of answer 29/03/2019 answer text <p>In November 2018, NHS England announced action to end the current variation in accessing flash glucose monitors. From April 2019 there will be a more consistent national approach to making these devices available. Clinical commissioning groups (CCGs) will be reimbursed to cover the costs of flash glucose monitoring sensors for those type 1 diabetes patients who are most likely to benefit from their use. NHS England has published detailed criteria and supporting guidance at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2019/03/flash-glucose-monitoring-national-arrangements-funding.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2019/03/flash-glucose-monitoring-national-arrangements-funding.pdf</a></p><p> </p><p>CCGs will be reimbursed for the cost of flash glucose monitoring sensors for those who meet these criteria, which could amount to up to 20% of their type 1 diabetes populations. CCGs can also locally choose to fund flash glucose monitoring for other patients with diabetes. The guidance advises that as part of their annual review process, patients with diabetes should be assessed for suitability for flash glucose monitoring. This process can also form part of a review for a different purpose, if that occurs earlier. This will promote a systematic approach to increasing take up.</p><p> </p><p>NHS England has engaged with NHS Clinical Commissioners, the membership organisation for CCGs, regarding the planned arrangements so that they can advise their members as appropriate. An FAQ for patients and commissioners is also being prepared and will be published, to aid the implementation. NHS England is also in conversations with the Academic Health Science Network to identify the capacity and scope for them to aid in rolling out flash glucose monitoring.</p><p> </p><p>Due to the limitations of the data collected by the NHS Business Services Authority, it is not possible to conclusively state which CCGs do or do not currently prescribe flash glucose monitors.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 236412 236414 question first answered 29/03/2019 14:47:45 answering member 4008 label Biography information for Dame Caroline Dinenage previous answer version 110770 answering member constituency Gosport answering member printed Caroline Dinenage answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1579 label Biography information for Mary Creagh

1104800

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, which CCGs do not currently prescribe Flash Glucose Monitoring kits.
tabling member constituency	Wakefield
tabling member printed	Mary Creagh
uin	236414
answer	answer is ministerial correction date of answer 29/03/2019 answer text <p>In November 2018, NHS England announced action to end the current variation in accessing flash glucose monitors. From April 2019 there will be a more consistent national approach to making these devices available. Clinical commissioning groups (CCGs) will be reimbursed to cover the costs of flash glucose monitoring sensors for those type 1 diabetes patients who are most likely to benefit from their use. NHS England has published detailed criteria and supporting guidance at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2019/03/flash-glucose-monitoring-national-arrangements-funding.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2019/03/flash-glucose-monitoring-national-arrangements-funding.pdf</a></p><p> </p><p>CCGs will be reimbursed for the cost of flash glucose monitoring sensors for those who meet these criteria, which could amount to up to 20% of their type 1 diabetes populations. CCGs can also locally choose to fund flash glucose monitoring for other patients with diabetes. The guidance advises that as part of their annual review process, patients with diabetes should be assessed for suitability for flash glucose monitoring. This process can also form part of a review for a different purpose, if that occurs earlier. This will promote a systematic approach to increasing take up.</p><p> </p><p>NHS England has engaged with NHS Clinical Commissioners, the membership organisation for CCGs, regarding the planned arrangements so that they can advise their members as appropriate. An FAQ for patients and commissioners is also being prepared and will be published, to aid the implementation. NHS England is also in conversations with the Academic Health Science Network to identify the capacity and scope for them to aid in rolling out flash glucose monitoring.</p><p> </p><p>Due to the limitations of the data collected by the NHS Business Services Authority, it is not possible to conclusively state which CCGs do or do not currently prescribe flash glucose monitors.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 236412 236413 question first answered 29/03/2019 14:47:45 answering member 4008 label Biography information for Dame Caroline Dinenage previous answer version 110772 answering member constituency Gosport answering member printed Caroline Dinenage answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1579 label Biography information for Mary Creagh

1251893

registered interest
date	13/11/2020
answering body	Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Chancellor of the Exchequer, what assessment he has made of the merits of increasing funding for diabetes technology in the Spending Review.
tabling member constituency	Twickenham
tabling member printed	Munira Wilson
uin	92019
answer	answer is ministerial correction date of answer 23/11/2020 answer text <p>I recognise the major impact that diabetes has on society and would like to assure you that the Government is committed to continuing to improve diabetes care within the NHS.</p><p> </p><p>While it would not be appropriate to respond in detail at this stage of the Spending Review, I can assure you that the issues you’ve raised have been noted.</p> answering member constituency North East Cambridgeshire answering member printed Steve Barclay question first answered 23/11/2020 08:32:00 answering member 4095 label Biography information for Steve Barclay
tabling member	4776 label Biography information for Munira Wilson